Literature DB >> 4372291

Human T lymphocyte "E" rosette function. I. A process modulated by intracellular cyclic AMP.

F V Chisari, T S Edgington.   

Abstract

The capacity of normal human T lymphocytes to form rosettes with sheep red blood cells can be inhibited by drugs or agents which induce elevations in intracellular levels of cyclic AMP. The effect is early in the presence of agents which elicit rapid elevations in intracellular cyclic AMP (isoproterenol, aminophylline) and occurs later in the presence of cholera toxin which induces a dalayed increase in endogenous cyclic AMP. Dibutyryl cyclic AMP is inhibitory, and the effects of dibutyryl cyclic AMP and the adenyl cyclase stimulators are potentiated by inhibition of phosphodiesterase. These data provide substantial evidence that elevation of intracellular cyclic AMP diminishes E rosette function of lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4372291      PMCID: PMC2139637          DOI: 10.1084/jem.140.4.1122

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  14 in total

1.  The role of cyclic 3',5' adenosine monophosphate in the specific cytolytic activity of lymphocytes.

Authors:  C S Henney; H R Bourne; L M Lichtenstein
Journal:  J Immunol       Date:  1972-06       Impact factor: 5.422

2.  Surface markers on human lymphocytes: studies of normal subjects and of patients with primary immunodeficiencies.

Authors:  F Aiuti; V Lacava; J A Garofalo; R D'Amelio; C D'Asero
Journal:  Clin Exp Immunol       Date:  1973-09       Impact factor: 4.330

3.  Peripheral blood lymphocyte cell surface markers during the course of systemic lupus erythematosus.

Authors:  R P Messner; F D Lindström; R C Williams
Journal:  J Clin Invest       Date:  1973-12       Impact factor: 14.808

4.  Effects of cholera toxin on in vitro models of immediate and delayed hypersensitivity. Further evidence for the role of cyclic adenosine 3',5'-monophosphate.

Authors:  L M Lichtenstein; C S Henney; H R Bourne; W B Greenough
Journal:  J Clin Invest       Date:  1973-03       Impact factor: 14.808

5.  Effects of cholera enterotoxin on adenosine 3',5'-monophosphate and neutrophil function. Comparison with other compounds which stimulate leukocyte adenyl cyclase.

Authors:  H R Bourne; R I Lehrer; L M Lichtenstein; G Weissmann; R Zurier
Journal:  J Clin Invest       Date:  1973-03       Impact factor: 14.808

6.  Hemolytic plaque formation by leukocytes in vitro. Control by vasoactive hormones.

Authors:  K L Melmon; H R Bourne; Y Weinstein; G M Shearer; J Kram; S Bauminger
Journal:  J Clin Invest       Date:  1974-01       Impact factor: 14.808

7.  Mechanisms of lysosomal enzyme release from human leukocytes. II. Effects of cAMP and cGMP, autonomic agonists, and agents which affect microtubule function.

Authors:  R B Zurier; G Weissmann; S Hoffstein; S Kammerman; H H Tai
Journal:  J Clin Invest       Date:  1974-01       Impact factor: 14.808

8.  Thymus-derived rosette-forming cells in various human disease states: cancer, lymphoma, bacterial and viral infections, and other diseases.

Authors:  J Wybran; H H Fudenberg
Journal:  J Clin Invest       Date:  1973-05       Impact factor: 14.808

9.  Immunoglobulin spots on the surface of rabbit lymphocytes.

Authors:  B Pernis; L Forni; L Amante
Journal:  J Exp Med       Date:  1970-11       Impact factor: 14.307

10.  Surface markers on human T and B lymphocytes. I. A large population of lymphocytes forming nonimmune rosettes with sheep red blood cells.

Authors:  M Jondal; G Holm; H Wigzell
Journal:  J Exp Med       Date:  1972-08-01       Impact factor: 14.307

View more
  22 in total

1.  Rosette formation by human T and B lymphocytes in the presence of adrenergic and cholinergic drugs.

Authors:  G G Ferreira; H K Brascher; M Q Javierre; W A Sassine; A O Lima
Journal:  Experientia       Date:  1976-12-15

2.  Spontaneous and PHA-induced rosetting of human blood, tonsil lymphocytes and MLC blasts with sheep, human and horse erythrocytes.

Authors:  P Gergely; F Vanky; E Klein
Journal:  Clin Exp Immunol       Date:  1976-07       Impact factor: 4.330

3.  Clinical significance of immunopathological findings in patients with post-pericardiotomy syndrome. II. The significance of serum inhibition and rosette inhibitory factors.

Authors:  B Maisch; P Schuff-Werner; P A Berg; K Kochsiek
Journal:  Clin Exp Immunol       Date:  1979-11       Impact factor: 4.330

4.  Active E rosette formation by human lymphoblasts.

Authors:  G Semenzato; G Amadori; P Sarasin; G Gasparotto
Journal:  Immunology       Date:  1978-04       Impact factor: 7.397

5.  Theophylline modulation of E-rosette formation: an indicator of T-cell maturation.

Authors:  S Limatibul; A Shore; H M Dosch; E W Gelfand
Journal:  Clin Exp Immunol       Date:  1978-09       Impact factor: 4.330

6.  Localization of T and B cells and alpha fetoprotein in hepatic biopsies from patients with liver disease.

Authors:  G Husby; R G Strickland; J L Caldwell; R C Williams
Journal:  J Clin Invest       Date:  1975-11       Impact factor: 14.808

7.  Suppressor effects of histamine on SK/SD delayed hypersensitivity reactions in man and on E-rosette-forming cells.

Authors:  U Ambanelli; G F Ferraccioli; P Mangenelli; G L Vanona
Journal:  Agents Actions       Date:  1979-12

8.  Inhibition of E-rosette formation and phagocytosis by human blood leucocytes after treatment with the dengue virus-induced cytotoxic factor.

Authors:  U C Chaturvedi; L Gulati; A Mathur
Journal:  Immunology       Date:  1982-04       Impact factor: 7.397

9.  Effects of cholera exotoxin on Fc receptor activity of lymphoid cells and mononuclear phagocytes.

Authors:  S H Zuckerman; S D Douglas
Journal:  Immunology       Date:  1977-03       Impact factor: 7.397

10.  alpha-Adrenoceptor stimulated lymphocytes trigger the mechanical response of vas deferens: participation of arachidonic acid metabolites.

Authors:  E S Borda; M M de Bracco; S Cangiani; M Finiasz; L Sterin-Borda
Journal:  Br J Pharmacol       Date:  1984-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.